Loading
Immunologist who studies why tumours resist immunotherapy and directs the Goodman Cancer Institute, McGill University's cancer research institute in Montreal.
Professor John Stagg is Director of the Rosalind and Morris Goodman Cancer Institute at McGill University, succeeding Morag Park who completed a 12-year term as Director in September 2025. He is Professor in McGill's Department of Microbiology and Immunology and Associate Professor at the Faculty of Pharmacy, Universite de Montreal. His laboratory investigates how cancers develop resistance to immunotherapy, including the effect of adenosine on immune cells, and uses multi-omics data to identify targets and develop biologic anti-cancer treatments.
| Title | Journal | Year |
|---|---|---|
| The adenosine pathway in immuno-oncology | Nature Reviews Clinical Oncology | 2020 |
| CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer | Proceedings of the National Academy of Sciences | 2013 |
| Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies | Annual Review of Pharmacology and Toxicology | 2025 |
Shares Immunotherapy, Immune system and the tags leadership, clinician-scientist.
Shares Immunotherapy and the tags leadership, clinician-scientist, immunotherapy.
Shares the tags leadership, clinician-scientist, immunotherapy.
Shares Immune system and the tags clinician-scientist, immunotherapy.
Shares Immunotherapy and the tags leadership, clinician-scientist.
Shares the tags leadership, clinician-scientist, immunotherapy.
Shares the tags leadership, clinician-scientist, immunotherapy.
Shares the tags leadership, clinician-scientist, immunotherapy.